Optimize Care in
Vulnerable IBD Populations
Master the application of integrin-based therapies, frailty-based risk stratification, and treat-to-target monitoring in older adults and pregnant women.
> Anti-TNF prescribing inertia persists.
> Subcutaneous formulations underutilized.
> Frailty-based risk assessment ignored.
> Failure to adapt FCP monitoring in pregnancy.
The Mechanistic Gap
Despite robust evidence from the VARSITY trial demonstrating the superiority of gut-selective integrin inhibitors over anti-TNF agents in ulcerative colitis, community practice lags. Anti-TNF therapies remain the dominant first-line biologic, exposing vulnerable populations to unnecessary systemic immunosuppression.
The VARSITY Evidence
In a head-to-head trial of Vedolizumab vs. Adalimumab for moderate-to-severe UC:
Gut-Selectivity Advantage
Blocking the alpha4beta7 integrin prevents lymphocyte trafficking exclusively to the GI tract via MAdCAM-1.
- ✓Lower exposure-adjusted infection rates.
- ✓Avoids systemic immunosuppression.
- ✓Preferred agent in elevated infection-risk cohorts.
High-Risk Scenarios
Navigate the specific safety hierarchies and monitoring adaptations required for older adults and pregnant women.
T2T Biomarker Simulation
Routine endoscopy is contraindicated for Elena in the first trimester and poses major risks for Arthur due to frailty. Use Fecal Calprotectin to objectively monitor mucosal inflammation without procedural risks.
Final Exam
Complete these 4 clinical cases to earn 1.5 AMA PRA Category 1 Credits™.